Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 3,263 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo first Clear all

Conditions: Non Small Cell Lung Cancer (NSCLC)
Interventions: Dacomitinib, Doxycycline, Probiotic, Alclometasone cream; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 79
States / cities: Duarte, California • Fullerton, California • Irvine, California + 49 more

Conditions: Phenylketonuria
Interventions: Sapropterin dihydrochloride, Placebo; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 8 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 26
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 23 more

Conditions: Infertility
Interventions: Follitropin delta, Placebo; Drug · Other
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 23
States / cities: Tempe, Arizona • Encino, California • Farmington, Connecticut + 20 more

Conditions: Degenerative Arthritis and Postoperative Pain
Interventions: Placebo, Gapabentin; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Influenza
Interventions: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 4,561 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 30
States / cities: Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 27 more

Conditions: Pediatric Obesity
Interventions: NOURISH, Wellness Group; Behavioral · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Healthy
Interventions: LY3985297, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Anaheim, California • Salt Lake City, Utah

Conditions: Healthy
Interventions: BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Acute Kidney Injury
Interventions: RMC-035, Placebo; Drug
Lead sponsor: Guard Therapeutics AB; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Fort Wayne, Indiana • Lincoln, Nebraska • Rochester, New York + 5 more

Conditions: Rheumatoid Arthritis
Interventions: Etanercept, Methotrexate, Placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Dental Caries
Interventions: C16G2 Gel, Placebo; Drug · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Imperial Beach, California • Indianapolis, Indiana • Boston, Massachusetts + 6 more

Conditions: Impotence, Prostatic Neoplasms
Interventions: Sildenafil therapy plus post-NSRRP HBO2T, Sildenafil therapy plus sham post-NSRRP HBO2T; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Psychological Effects of Study Drug
Interventions: Lactose (inactive placebo), midomafetamine HCl; Drug
Lead sponsor: Resilient Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2022
U.S. locations: 3
States / cities: Boulder, Colorado • Santa Fe, New Mexico • Mt. Pleasant, South Carolina

Conditions: Systemic Juvenile Idiopathic Arthritis
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 19 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Pain Uterus
Interventions: Fentanyl, placebo; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 14 Years and older · Female only
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Honolulu, Hawaii • Portland, Oregon

Conditions: Chronic Kidney Diseases
Interventions: Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan; Drug
Lead sponsor: University Medical Center Groningen; Other
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Gastric Cancer
Interventions: 5-Fluoruracil, Folinic acid, Onartuzumab, Oxaliplatin, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 15
States / cities: Los Angeles, California • Denver, Colorado • Fort Myers, Florida + 11 more

Conditions: Chronic Obstructive Pulmonary Disease, COPD, Chronic Bronchitis
Interventions: Inhaled 7% HS (NaCl) home treatment; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Narcolepsy Type 1 (NT1)
Interventions: VX-433, Placebo, Midazolam, Bupropion; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Acute Myeloid Leukemia
Interventions: vosaroxin + cytarabine, placebo + cytarabine; Drug
Lead sponsor: Sunesis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 38
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 31 more

Conditions: Rhinovirus Infection
Interventions: VPV 1000 mg, VPV 500 mg, Placebo; Drug · Other
Lead sponsor: Altesa Biosciences, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 37
States / cities: Mobile, Alabama • Tempe, Arizona • Inglewood, California + 33 more

Conditions: Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders
Interventions: Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo, Matching Intramuscular Placebo, My-E-Health SENTINEL Digital Monitoring and Human-Gated Escalation Platform, Standardized Psychological Preparation, Integration and Recovery Support, Garmin-Enabled Longitudinal Wellness Monitoring; Drug · Device · Behavioral + 1 more
Lead sponsor: Clive Michelsen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Basalt, Colorado

Conditions: 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions: Famotidine, Celecoxib, Placebo; Drug
Lead sponsor: Leidos Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more

Conditions: Cardiovascular
Interventions: AMG 529, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)

Effect of Gabapentin on Orthopedic Pain

Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years

NOURISH: Nourishing Our Understanding of Role Modeling to Improve Support and Health

A First-In-Human Study of LY3985297 in Healthy Participants

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery

Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis

Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

Intranasal Fentanyl for Pain Control During First-Trimester Uterine Aspiration

Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

Sustained Effects of Hypertonic Saline on Mucociliary Clearance in Subjects With Chronic Bronchitis

A Phase 1, First-in-human Study of VX-433

Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD

Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

AMG 529 First in Human Study